Public Health Webinar Series on Blood Disorders
CDC’s Division of Blood Disorders (DBD) is proud to offer its Public Health Webinar Series on Blood Disorders. The purpose of this series is to provide evidence-based information on new research, interventions, emerging issues of interest in blood disorders, as well as innovative approaches in collaborations and partnerships. We invite you to join us in this series.
Archives for 2020
July 16, 2020
Veronica H. Flood, MD
Professor of Pediatrics, Division of Hematology/Oncology, Medical College of Wisconsin
Associate Medical Director, Comprehensive Center for Bleeding Disorders
Associate Investigator, Versiti Blood Research Institute
In this webinar, Dr. Flood will review the diagnostic approach to von Willebrand Disease (VWD), including the assessment of bleeding history and the utilization of laboratory measurements, as well as the challenges and advances to this approach. She will also share insights from the Zimmerman Program for the Molecular and Clinical Biology of VWD, a national study of VWD in the United States.
June 18, 2020
Sujit Sheth, MD
Harold Weill Professor, Chief of Pediatric Hematology and Oncology, and Vice Chair for Clinical Research, Department of Pediatrics, Weill Cornell Medicine
Director, New York Comprehensive Thalassemia Center, New York-Presbyterian Hospital/Weill Cornell Medical Center
The thalassemia syndromes are among the most common genetic disorders. Homozygous or compound heterozygotes have a wide spectrum of clinical severity, with the most severe requiring regular blood transfusions to maintain health and prevent morbidity. Transfusion-associated iron overload and its complications result in significant morbidity and mortality, thus disease-modifying treatments are a major unmet need in the management of these individuals.
During the past five years, novel approaches to treatment have been possible with advances in technology. In this webinar, Dr. Sheth will discuss the basic pathophysiology of the disease and specific targets for novel therapies. He will review data from trials of the newer agents aimed at reducing or abolishing the transfusion burden and mention additional strategies that are in early stage development that have the potential to completely change the landscape of thalassemia care.
March 5, 2020
Holger J. Schünemann, MD, MSc, PhD, FRCPC
Professor of Clinical Epidemiology and of Medicine
Departments of Health Research Methods, Evidence, and Impact and of Medicine
Director, Cochrane Canada and McMaster GRADE Centre
Hamilton, Ontario, Canada
Andrea Darzi, MD, MPH, PhD Candidate
Project Coordinator, Cochrane Canada
Department of Health Research Methods, Evidence, and Impact
Hamilton, Ontario, Canada
Selection of a Risk Assessment Model for VTE Prevention in Hospitalized Medical Patientsexternal icon
Venous thromboembolism (VTE), comprising deep vein thrombosis and pulmonary embolism, has an annual incidence in adult populations of approximately 1 per 1,000, and is a major burden in hospitalized medical patients. The risk of hospital-acquired VTE is reduced by using pharmacological and non-pharmacological interventions, but these interventions are not without potential patient harms.
Risk assessment models (RAMs) have been developed and employed to stratify hospitalized medically ill patients according to their risk of having VTE or a clinically significant bleeding event. Stratum-specific strategies optimizing patient management to prevent both VTE and bleeding events are recommended. RAMs are developed using data registries but ideally should also be informed by a systematic synthesis of all current evidence of potential risk factors.
In this webinar, Drs. Schünemann and Darzi will present the process and findings of a systematic review and a novel approach they conducted to identify risk factors for VTE and bleeding in hospitalized medical patients and develop RAMs. They will also highlight how these findings inform patient management, the validation of RAMs for hospitalized medical patients, and future guideline recommendations.
February 13, 2020
Steven Pipe, MD
Chair, Medical and Scientific Advisory Council, National Hemophilia Foundation
Director, Division of Pediatric Hematology and Oncology
Pediatric Medical Director, Hemophilia and Coagulation Disorders Program
Director, Special Coagulation Laboratory, University of Michigan
Margaret Ragni, MD, MPH
Professor of Medicine, University of Pittsburgh Department of Medicine, Division of Hematology/Oncology
Professor of Clinical Translational Science at the Clinical Translational Science Institute University of Pittsburgh
Director, Hemophilia Center of Western Pennsylvania
Inhibitor formation is a serious complication of hemophilia treatment that occurs in 30% of patients at highest risk – youth with severe hemophilia A. To develop a road map for needed research in this area, working groups met in 2019 at a State of the Science Symposium at the National Heart, Lung, and Blood Institute.
In this webinar, Drs. Pipe and Ragni discuss the progress and challenges in the design and implementation of research studies to prevent and eradicate inhibitors.
For more information on the webinar series, please contact Cindy Sayers at firstname.lastname@example.org.